Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury
New Jersey
08512
United States
Website: http://www.amicusrx.com/
Email: info@amicusrx.com
About Amicus Therapeutics, Inc.
Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases. We have a unique set of platform technologies and medicines in development for people living with rare and devastating diseases, including the Lysosomal Storage Disorders Fabry disease and Pompe disease, as well as the genetic connective skin disorder Epidermolysis Bullosa (EB).
The needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. Our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers.
344 articles with Amicus Therapeutics, Inc.
-
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
6/8/2021
Positive Scientific Opinion Under Early Access to Medicines Scheme (EAMS) Recognizes High Unmet Medical Need in ERT Treated Late-Onset Pompe Disease Patients
-
Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
5/28/2021
Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference, being held virtually on Wednesday, June 9, 2021 at 5:30 p.m. E.T.
-
Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases
5/21/2021
Amicus Therapeutics, announced two posters for presentation highlighting its development program for Pompe disease at the 16th International Congress on Neuromuscular Diseases being held virtually, May 21-22 and 28-29, 2021.
-
Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
5/10/2021
Galafold® (migalastat) PerformanceReflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M
-
Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
5/7/2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in May: Bank of America 2021 Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. E.T. UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 10:00 a.m. E.T.
-
Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development
5/6/2021
Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization
-
Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 24th Annual Meeting
5/5/2021
Amicus Therapeutics (Nasdaq: FOLD), today announced the acceptance of two abstracts for presentation at the American Society of Gene & Cell Therapy 24th Annual Meeting being held virtually, May 11-14, 2021. Accepted abstracts will highlight preclinical data from the Company’s Fabry and Pompe gene therapy programs, which Amicus is developing with the Gene Therapy Program of the Perelman School of Medicine at the University of Pennsylvania.
-
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
5/3/2021
Amicus Therapeutics announced the completion of a successful Type B Pre-Biologics License Application meeting with the U.S. Food and Drug Administration for AT-GAA, its investigational two-component therapy for the treatment of Pompe disease.
-
Amicus Therapeutics Recognized as a Great Place to Work® in EuropeGreat Place to Work® Certification in the United Kingdom, Spain, Italy and Germany
4/28/2021
Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has been recognized by the prestigious Great Place to Work® Institute as among the best places to work in the United Kingdom, Spain, Italy and Germany.
-
Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
4/26/2021
Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2021.
-
Amicus Therapeutics Announces Presentation and Posters at the 2021 MDA Clinical & Scientific Conference
3/15/2021
Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2021 MDA Virtual Clinical & Scientific Conference to be held March 15-18, 2021. Oral Platform Presentation: Thursday, March 18, 5:30 – 5:45 p.m. ET
-
Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates
3/1/2021
Amicus Therapeutics, a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, announced financial results for the full year ended December 31, 2020.
-
Agilent is one of seven health care companies to make the fourth annual list of 100 companies compiled by the publication.
-
Amicus Therapeutics to Present at Upcoming Investor Conferences - Feb 18, 2021
2/18/2021
Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences
-
Amicus Therapeutics to Announce Full-Year 2020 Financial Results on March 1, 2021
2/17/2021
Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, March 1, 2021 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2020.
-
Clinical Catch-Up: February 8-12
2/15/2021
It was a busy week for clinical trial announcements and news. Here’s a look. -
Amicus Therapeutics announced topline results from its Phase III PROPEL pivotal trial of AT-GAA (cipaglucosidase alfa and miglustat) for late-onset Pompe disease (LOPD). Although the results showed some positive data, it failed to hit the primary endpoint.
-
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
2/11/2021
Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021
-
Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021
2/8/2021
Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses Further Validates Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies to Develop Next Generation Gene Therapies
-
Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021
2/8/2021
Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease Plan to Submit IND for Next Clinical Study in 2H2021